Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Lineage Therap, retaining the price target of $9.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors including the successful administration of OPC1 to a chronic spinal cord injury patient using a new delivery system. This marks a significant milestone as it is the first time OPC1 has been delivered to a chronic SCI patient, potentially expanding the treatable population. The new delivery system allows for a more efficient administration process, reducing the need for extensive preparation and ventilation support.
Additionally, the ongoing DOSED study aims to build on previous positive clinical outcomes in SCI patients, focusing on both subacute and chronic conditions. The study prioritizes safety and has shown promising results in earlier trials, with no adverse neurological effects and notable motor improvements in patients. These advancements suggest a strong potential for Lineage’s lead asset, which is likely to attract investor interest and support the Buy rating.